Vospalitel'nye zabolevaniya organov malogo taza: prosto o slozhnom
- Authors: Sekhin S.V1
-
Affiliations:
- ГБОУ ВПО Смоленская государственная медицинская академия Минздрава РФ
- Issue: Vol 14, No 6 (2012)
- Pages: 48-53
- Section: Articles
- URL: https://journal-vniispk.ru/2075-1753/article/view/93620
- ID: 93620
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##References
- Sweet R.L., Gibbs R.S. Pelvic inflammatory disease. In: Infectious diseases of female genital tract. Philadelphia: Lippincott Williams & Wilkins, 2009; p. 220–44.
- Centers for Disease Control and Prevention. Sexually Transmitted Diseases Treatment Guidelines, 2010. Morbidity and Mortality Weekly Report 2010; 59 (RR-12): 110.
- Westrom L.V. Sexually transmitted diseases and infertility. Sexually Transmitted Diseases 1994; 21 (Suppl.): 532–7.
- Westrom L.V., Joesoef R, Reynolds G et al. Pelvic inflammatory disease and infertility. A cohort study of 1844 women with laparoscopically verified disease and 657 control women with normal laparoscopic results. Sexually Transmitted Diseases 1992; 19: 185–92.
- Westrom L.V., Berger G.S. Consequences of pelvic inflammatory disease. Pelvic inflammatory disease. New York: Raven Press, 1992; p. 101–14.
- Hillis S.D., Joesoef R, Marchbanks P.A. et al. Delayed care of pelvic inflammatory disease is a risk factor for impaired fertility. Am J Obstet Gynecol 1993; 168: 1503–9.
- Ross J, Judlin P, Nilas L. European guideline for the management of pelvic inflammatory disease. Int J STD AIDS 2007; 18: 662–6.
- Sweet R.L. Treatment of acute pelvic inflammatory disease. Infect Dis Obstet Gynecol 2011.
- Ness R.B., Soper D.E., Holley R.L. et al. Effectiveness of inpatient and outpatient treatment strategies for women with pelvic inflammatory disease: results from the pelvic inflammatory disease evaluation and clinical health (PEACH) randomized trial. Am J Obstet Gynecol 2002; 186 (5): 929–37.
- Manhart L.E., Critchlow C.W., Holmes K.K. et al. Mucopurulent cervicitis and Mycoplasma genitalium. J Infect Dis 2003; 187 (4): 650–7.
- Pépin J, Labbé A.C., Khonde N et al. Mycoplasma qenitalium: an organism commonly associated with cervicitis among west African sex workers. Sex Transmit Infect 2005; 81 (1): 67–72.
- Moller B.R., Taylor-Robinson D, Furr P.M., Freundt E.A. Acute upper genital - tract disease in female monkeys provoked experimentally by Mycoplasma genitalium. Br J Experiment Pathology 1985; 66 (4): 417–26.
- Barzynska A, Funch P, Fedder J et al. Morphology of human Fallopian tubes after infection with Mycoplasma genitalium and Mycoplasma hominis: In vitro organ culture study. Hum Reprod 2007; 22 (4): 968–79.
- Практическое руководство по антиинфекционной химиотерапии. Под ред. Л.С.Страчунского, Ю.Б.Белоусова, С.Н.Козлова. Смоленск: МАКМАХ, 2007.
- Bauernfeind A. Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin. J Antimicrob Chemother 1997; 40 (5): 639–51.
- Aldridge K.E., Ashcraft D.S. et al. Comparison of the in vitro activities of Bay 12-8039, a new quinolone, and other antimicrobials against clinically important anaerobes. Antimicrob Agents Chemotherapy 1997; 41 (3): 709–11.
- Woodcock J.M., Andrews J.M., Boswell F.J. et al. In vitro activity of BAY 12-8039, a new fluoroquinolone. Antimicrob Agents Chemotherapy 1997; 41: 101–6.
- Dalhoff A. In vitro activities of quinolones. Expert opinion on investigational drugs 1999; 8 (2); 123–37.
- Bebear C.M., de Barbeyrac B, Pereyre S et al. Activity of moxifloxacin against the urogenital mycoplasmas Ureaplasma spp., Mycoplasma hominis and Mycoplasma genitalium and Chlamydia trachomatis. Clin Microbiol Infect 2008; 14 (8): 801–5.
- Sullivan J.T., Woodruff M, Lettieri J et al. Pharmacokinetics of a once - daily oral dose of moxifloxacin (Bay 12-8039), a new enantiomerically pure 8-methoxy quinolone. Antimicrob Agents Chemotherapy 1999; 43 (11): 2793–7.
- Stass H, Kubitza D, Aydeniz B et al. Penetration and accumulation of moxifloxacin in uterine tissue. Int J Gynaecol Obstet 2008; 102 (2): 132–6.
- Ross J.D., Cronje H.S., Paszkowski T et al. Moxifloxacin versus ofloxacin plus metronidazole in uncomplicated pelvic inflammatory disease: results of a multicentre, double blind, randomised trial. Sex Transmitd Infect 2006; 82 (6): 446–51.
- Heystek M, Ross J.D., PID Study Group. A randomized double - blind comparison of moxifloxacin and doxycycline/metronidazole/ciprofloxacin in the treatment of acute, uncomplicated pelvic inflammatory disease. Internat J STD AIDS 2009; 20 (10): 690–5.
- Judlin P, Liao Q, Liu Z et al. Efficacy and safety of moxifloxacin in uncomplicated pelvic inflammatory disease: the MONALISA study. BJOG: Int J Obstet Gynaecol 2010; 117 (12): 1475–84.
- Mu Y, Huang J, Liu R et al. Efficacy and safety profile of moxifloxacin in treatment of urogenital system infections: A meta - analysis of randomized controlled trials. African J Pharmacy Pharmacol 2012; 6 (26): 1910–22.
- Walker C.K., Sweet R.L. Management. In: Sweet R.L., Wiesenfeld H.C. editors. Pelvic Inflammatory Disease. London: Taylor & Francis, 2006; p. 141–56.
- Ross J, Mc Carthy G. UK National Guideline for the management of Pelvic Inflammatory Disease 2011. British Association for Sexual Health and HIV, 2011. www.bashh.org/documents/3205.
Supplementary files
